Endo International PLC (NASDAQ:ENDP) (TSE:ENL) – Research analysts at G.Research raised their FY2019 earnings per share (EPS) estimates for shares of Endo International in a report released on Wednesday, November 6th. G.Research analyst K. Kedra now forecasts that the company will post earnings per share of $2.20 for the year, up from their prior estimate of $2.15. G.Research also issued estimates for Endo International’s FY2020 earnings at $2.35 EPS, FY2021 earnings at $2.10 EPS, FY2022 earnings at $1.65 EPS and FY2023 earnings at $1.55 EPS.
Endo International (NASDAQ:ENDP) (TSE:ENL) last issued its earnings results on Monday, November 4th. The company reported $0.60 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.53 by $0.07. Endo International had a negative net margin of 16.89% and a negative return on equity of 99.08%. The company had revenue of $729.00 million for the quarter, compared to the consensus estimate of $709.01 million. During the same quarter in the previous year, the company earned $0.71 EPS. The firm’s revenue for the quarter was down 2.1% compared to the same quarter last year.
Several other equities research analysts also recently commented on ENDP. Mizuho restated a “hold” rating and issued a $6.00 target price on shares of Endo International in a research note on Wednesday, August 7th. BidaskClub upgraded shares of Endo International from a “strong sell” rating to a “sell” rating in a research report on Friday, October 18th. Morgan Stanley set a $2.00 price target on shares of Endo International and gave the stock a “sell” rating in a research report on Friday, August 9th. Royal Bank of Canada reiterated a “hold” rating and set a $6.00 price target on shares of Endo International in a research report on Thursday, August 8th. Finally, ValuEngine downgraded shares of Endo International from a “hold” rating to a “sell” rating in a research report on Thursday. Four analysts have rated the stock with a sell rating, eleven have issued a hold rating and two have issued a buy rating to the company’s stock. Endo International presently has an average rating of “Hold” and a consensus target price of $7.89.
Shares of NASDAQ:ENDP traded up $0.02 on Friday, hitting $4.25. The stock had a trading volume of 198,049 shares, compared to its average volume of 11,003,127. Endo International has a twelve month low of $1.97 and a twelve month high of $15.75. The firm’s 50 day moving average price is $4.01 and its 200-day moving average price is $4.35. The company has a market capitalization of $1.01 billion, a price-to-earnings ratio of 1.47 and a beta of 1.41.
In other Endo International news, Director Roger H. Kimmel sold 25,000 shares of the company’s stock in a transaction dated Monday, September 16th. The shares were sold at an average price of $4.09, for a total transaction of $102,250.00. Following the transaction, the director now directly owns 123,309 shares in the company, valued at approximately $504,333.81. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. 1.50% of the stock is owned by corporate insiders.
Institutional investors have recently added to or reduced their stakes in the business. Paloma Partners Management Co acquired a new position in Endo International during the 2nd quarter valued at about $98,000. Meeder Asset Management Inc. lifted its position in Endo International by 47.1% during the 2nd quarter. Meeder Asset Management Inc. now owns 37,887 shares of the company’s stock valued at $156,000 after purchasing an additional 12,127 shares during the period. Nisa Investment Advisors LLC lifted its position in Endo International by 14.5% during the 3rd quarter. Nisa Investment Advisors LLC now owns 50,690 shares of the company’s stock valued at $163,000 after purchasing an additional 6,434 shares during the period. Commonwealth Bank of Australia lifted its position in Endo International by 41.6% during the 2nd quarter. Commonwealth Bank of Australia now owns 66,400 shares of the company’s stock valued at $273,000 after purchasing an additional 19,500 shares during the period. Finally, Hunter Associates Investment Management LLC lifted its position in Endo International by 37.4% during the 2nd quarter. Hunter Associates Investment Management LLC now owns 94,075 shares of the company’s stock valued at $388,000 after purchasing an additional 25,625 shares during the period. Institutional investors own 95.20% of the company’s stock.
About Endo International
Endo International plc, a specialty pharmaceutical company, manufactures and sells generic and branded pharmaceuticals in the United States, Canada, and internationally. The company operates through three segments: U.S. Generic Pharmaceuticals, U.S. Branded Pharmaceuticals, and International Pharmaceuticals.
Read More: Buy Rating
Receive News & Ratings for Endo International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endo International and related companies with MarketBeat.com's FREE daily email newsletter.